Brokerages expect Jounce Therapeutics Inc (NASDAQ:JNCE) to post $15.64 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Jounce Therapeutics’ earnings, with estimates ranging from $15.00 million to $16.27 million. Jounce Therapeutics posted sales of $20.29 million in the same quarter last year, which suggests a negative year-over-year growth rate of 22.9%. The firm is expected to announce its next quarterly earnings results on Friday, March 9th.

On average, analysts expect that Jounce Therapeutics will report full-year sales of $15.64 million for the current year. For the next fiscal year, analysts forecast that the firm will report sales of $127.97 million per share, with estimates ranging from $74.92 million to $206.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Jounce Therapeutics.

Jounce Therapeutics (NASDAQ:JNCE) last posted its earnings results on Monday, November 13th. The company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.12. The business had revenue of $18.10 million during the quarter, compared to analyst estimates of $20.00 million. Jounce Therapeutics had a negative return on equity of 1.39% and a negative net margin of 2.03%. The company’s revenue was up 7.1% compared to the same quarter last year.

A number of research analysts have weighed in on the company. J P Morgan Chase & Co set a $28.00 target price on Jounce Therapeutics and gave the company a “buy” rating in a report on Monday, November 13th. Robert W. Baird reissued an “outperform” rating and set a $30.00 price objective on shares of Jounce Therapeutics in a report on Monday, September 18th. Finally, Zacks Investment Research raised Jounce Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 15th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $23.67.

Large investors have recently added to or reduced their stakes in the stock. Fosun International Ltd bought a new stake in Jounce Therapeutics in the 2nd quarter worth approximately $1,456,000. Conning Inc. lifted its position in Jounce Therapeutics by 36.0% in the third quarter. Conning Inc. now owns 125,960 shares of the company’s stock valued at $1,962,000 after purchasing an additional 33,350 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Jounce Therapeutics by 465.7% in the second quarter. Goldman Sachs Group Inc. now owns 69,648 shares of the company’s stock valued at $977,000 after purchasing an additional 57,336 shares during the last quarter. Geode Capital Management LLC bought a new stake in Jounce Therapeutics in the first quarter valued at approximately $1,573,000. Finally, Wells Fargo & Company MN lifted its position in Jounce Therapeutics by 476.1% in the second quarter. Wells Fargo & Company MN now owns 20,970 shares of the company’s stock valued at $294,000 after purchasing an additional 17,330 shares during the last quarter. Institutional investors own 47.55% of the company’s stock.

Jounce Therapeutics (NASDAQ:JNCE) traded up $0.47 during mid-day trading on Tuesday, reaching $14.61. The company’s stock had a trading volume of 158,100 shares, compared to its average volume of 157,262. Jounce Therapeutics has a 1-year low of $11.05 and a 1-year high of $29.29.

COPYRIGHT VIOLATION NOTICE: “Analysts Expect Jounce Therapeutics Inc (JNCE) Will Post Quarterly Sales of $15.64 Million” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/12/analysts-expect-jounce-therapeutics-inc-jnce-will-post-quarterly-sales-of-15-64-million.html.

About Jounce Therapeutics

Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.

Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Jounce Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.